Levodopa unresponsive symptoms in Parkinson disease
- PMID: 18781679
- DOI: 10.1002/mds.22049
Levodopa unresponsive symptoms in Parkinson disease
Abstract
Levodopa has been the mainstay of symptomatic therapy for Parkinson Disease (PD) for 40 years providing benefit to virtually all patients. Levodopa therapy results in improved activities of daily living, enhanced quality of life, and improved mortality. However, the long-term use of levodopa is associated with the development of motor fluctuations and dyskinesia. In addition, levodopa therapy has further limitations. It has little or no effect on certain motor features (e.g. gait and balance dysfunction) and a non-motor symptom complex (autonomic dysfunction, pain syndromes, sleep disorders, mood disturbances, dementia). Further, multiple case reports illustrate the potential of levodopa and other dopaminergic agents to cause or reveal a series of impulse control disorders. This review highlights the levodopa unresponsive symptoms in PD.
(c) 2008 Movement Disorder Society.
Similar articles
-
Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):12-7. J Am Med Dir Assoc. 2006. PMID: 17948614 Review.
-
[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].Fortschr Neurol Psychiatr. 2007 Apr;75(4):236-41. doi: 10.1055/s-2007-959188. Fortschr Neurol Psychiatr. 2007. PMID: 17427044 German.
-
Levodopa-related motor complications--phenomenology.Mov Disord. 2008;23 Suppl 3:S509-14. doi: 10.1002/mds.22021. Mov Disord. 2008. PMID: 18781677 Review.
-
Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.Mov Disord. 2002 Nov;17(6):1227-34. doi: 10.1002/mds.10244. Mov Disord. 2002. PMID: 12465061
-
Levodopa in the early treatment of Parkinson's disease.Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S17-20. doi: 10.1016/S1353-8020(09)70006-9. Parkinsonism Relat Disord. 2009. PMID: 19131036 Review.
Cited by
-
Emotional state affects gait initiation in individuals with Parkinson's disease.Cogn Affect Behav Neurosci. 2012 Mar;12(1):207-19. doi: 10.3758/s13415-011-0071-9. Cogn Affect Behav Neurosci. 2012. PMID: 22194236 Free PMC article.
-
Protective effects of SKF-96365, a non-specific inhibitor of SOCE, against MPP+-induced cytotoxicity in PC12 cells: potential role of Homer1.PLoS One. 2013;8(1):e55601. doi: 10.1371/journal.pone.0055601. Epub 2013 Jan 31. PLoS One. 2013. PMID: 23383239 Free PMC article.
-
Cortical Activation During Finger Tapping Task Performance in Parkinson's Disease Is Influenced by Priming Conditions: An ALE Meta-Analysis.Front Hum Neurosci. 2021 Nov 30;15:774656. doi: 10.3389/fnhum.2021.774656. eCollection 2021. Front Hum Neurosci. 2021. PMID: 34916919 Free PMC article.
-
Gait variability in Parkinson's disease: levodopa and walking direction.Acta Neurol Scand. 2016 Jul;134(1):83-6. doi: 10.1111/ane.12505. Epub 2015 Sep 23. Acta Neurol Scand. 2016. PMID: 26399376 Free PMC article.
-
The Effect of Levodopa on Improvements in Protective Stepping in People With Parkinson's Disease.Neurorehabil Neural Repair. 2016 Nov;30(10):931-940. doi: 10.1177/1545968316648669. Epub 2016 May 9. Neurorehabil Neural Repair. 2016. PMID: 27162165 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical